Pulmonary Valve Articles & Analysis
11 news found
The Zephyr Valve is a minimally invasive treatment option that can deliver significant benefits to patients including improvements in lung function, exercise capacity, and quality of life.1 Placed by bronchoscopy, with no cutting or incision, the valves are for patients who remain symptomatic despite optimal management including medications, ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following ...
The AeriSeal System is not approved by the FDA or approved for commercial sale in the United States. About Zephyr Valves The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema. ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following ...
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July this year. ...
” Eliane Schutte, Xeltis CEO, added: “EIB financial support can make the difference in the time our restorative heart valves and blood vessels reach patients that today have limited or no options at all for their conditions. ...
Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue. ...
Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. ...
Colibri Heart Valve LLC, a privately held emerging medical device company, has received an Issue Notification from the U.S. ...